In order to decipher whether ATRX-deficient cells are sensitive to PDGFRi, we assessed the sensitivity of MOG-G-UVW, U-251, and SF-188 (EV and ATRX KO) high-grade glioma cell lines to the potent and selective PDGFRi, CP-673451. Here, ATRX is linked to central nervous system cancer.